News from arena pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 28, 2014, 18:20 ET

Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Phentermine HCl

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of lorcaserin...

Oct 27, 2014, 08:00 ET

Arena Pharmaceuticals Announces Third Quarter 2014 Conference Call and Webcast on Monday, November 3

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30...

Oct 13, 2014, 08:00 ET

Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for...

Oct 10, 2014, 11:36 ET
Eisai logo.  (PRNewsFoto/Eisai Inc.)

Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3...

Sep 22, 2014, 08:00 ET

Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the...

Sep 02, 2014, 08:00 ET

Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to...

Aug 01, 2014, 04:30 ET

Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30,...

Jul 30, 2014, 08:00 ET

Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that an article based on post-hoc analyses from the three pivotal...

Jul 29, 2014, 08:00 ET

Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that BELVIQ® (lorcaserin HCl) has been nominated by the Galien...

Jul 25, 2014, 08:00 ET

Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report second quarter 2014...

Jul 22, 2014, 02:00 ET

Arena Pharmaceuticals signe un accord de commercialisation et de fourniture de BELVIQ® (hydrochlorure de lorcasérine) en Israël

-- Abic Marketing Limited, une filiale de Teva, distribuera BELVIQ une fois l'homologation réglementaire reçue pour Israël --...

Jul 22, 2014, 02:00 ET

Arena Pharmaceuticals schließt Marketing- und Liefervereinbarung für BELVIQ® (lorcaserin HCl) in Israel ab

-- Tochtergesellschaft von Teva, Abic Marketing Limited, wird BELVIQ nach behördlicher Genehmigung in Israel vertreiben --  Arena...

Jul 21, 2014, 08:00 ET

Arena Pharmaceuticals Enters into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Israel

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an...

Jul 15, 2014, 16:31 ET

Arena Pharmaceuticals Issued Patent for APD371 by United States Patent and Trademark Office

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it was granted U.S. Patent No. 8,778,950, entitled "Cannabinoid Receptor...

Jul 10, 2014, 08:00 ET

Arena Pharmaceuticals Reports that Eisai Completes Planned Increase in Sales Force for BELVIQ® (lorcaserin HCl) CIV

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai Inc. has completed its planned increase of more than 200 new contract...

Jun 13, 2014, 08:00 ET

Arena Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 2014...

Jun 03, 2014, 08:00 ET

Arena Pharmaceuticals Initiates Phase 1b Clinical Trial of APD334 for Autoimmune Diseases

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a...

May 27, 2014, 08:00 ET

Arena Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Jefferies 2014...

May 12, 2014, 16:03 ET

Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2014 Financial Results

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31,...

May 09, 2014, 08:00 ET

Arena Pharmaceuticals Reports that Eisai Plans to Further Increase its Sales Force for BELVIQ® (lorcaserin HCl) CIV by 50%

 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported that Eisai plans to add more than 200 new contract sales representatives to its...